BK Virus Nephropathy in Renal Transplantation: Case Series and Review of the Literature

Basit Öğe Kaydı
dc.contributor.authorBaloglu, Ismail
dc.contributor.authorTurkmen, Kultigin
dc.contributor.authorEsen, Haci Hasan
dc.contributor.authorSelcuk, Nedim Yilmaz
dc.contributor.authorTonbul, Halil Zeki
dc.date.accessioned2024-02-23T14:41:18Z
dc.date.available2024-02-23T14:41:18Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractObjective: BK virus nephropathy (BKVN) is an important cause of kidney transplant failure. In this study, we aimed to evaluate our center's experience with BKVN in patients who had undergone renal transplantation and also discussed important aspects of the disease in this patient population. Materials and Methods: In this study, 8 patients with BKVN were evaluated retrospectively, having been selected from a group of 330 patients (178 females, 152 males; mean age: 48.37 +/- 13.25 years) who had undergone renal transplantation between 2007 and 2017 and were followed up at our center. Results: BKVN was detected in 8 of 330 renal transplantation patients (4 females, 4 males; mean age: 51.25 +/- 11.14 years). Their immunosuppressive regimen consisted of tacrolimus (FK), mycophenolate mofetil (MMF), and methylprednisolone. To reduce immunosuppressive dose, FK was discontinued in 3 patients, and they were switched to everolimus. In 2 of 7 patients, MMF was discontinued, and they were switched to azathioprine. FK or MMF doses were reduced in the8 patients with BKVN. Out of the 8 patients, cidofovir was administered to 1 patient, whereas intravenous immunoglobulins were administered to 3 patients. Additionally, pulse steroid treatment was administered to 1 patient who was diagnosed with acute rejection based on allograft biopsy findings. Among the 8 patients with BKVN, 1 (12.5%) experienced graft loss and was returned to hemodialysis treatment. Conclusion: Although new alternative treatments are available, immunosuppressive dose reduction is still considered the most effective treatment. Therefore, we believe that effective screening and preemptive strategies should be defined more clearly instead of focusing on treatment strategies.en_US
dc.identifier.doi10.5152/turkjnephrol.2020.3580
dc.identifier.endpage17en_US
dc.identifier.issn2667-4440
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85088145359en_US
dc.identifier.startpage12en_US
dc.identifier.urihttps://doi.org/10.5152/turkjnephrol.2020.3580
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16791
dc.identifier.volume29en_US
dc.identifier.wosWOS:000514116300003en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal Of Nephrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRenal Transplantationen_US
dc.subjectBk Virusen_US
dc.subjectBk Virus Nephropathyen_US
dc.titleBK Virus Nephropathy in Renal Transplantation: Case Series and Review of the Literatureen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu